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systematic review and meta-analysis
Yu-Chung Chuang1,2, Jann-Tay Wang1*, Hsin-Yi Lin3 and Shan-Chwen Chang1
Abstract
Background: Linezolid, which has bacteriostatic activity, is approved for the treatment of vancomycin-resistant
enterococci (VRE) infections. Meanwhile, daptomycin exerts bactericidal activity against VRE, but is not approved for
the treatment of VRE bacteremia. Only a few studies with small sample sizes have compared the effectiveness of
these drugs for treatment of VRE bacteremia.
Methods: PubMed, EMBASE, and the Cochrane Library were searched for studies of VRE bacteremia treatment
published before January 1, 2014. All studies reporting daptomycin and linezolid treatment outcomes
simultaneously were included. The endpoints were mortality and microbiological cure. The adjusted odds ratios
(aORs) of mortality in daptomycin- and linezolid-treated patients were extracted if available. Pooled odds ratios
(ORs) and 95% confidence intervals (CIs) were calculated for all outcomes using a random-effects model.
Results: Thirteen studies (532 patients receiving daptomycin, 656 patients receiving linezolid) met the selection criteria.
All studies had retrospective cohort designs and relatively small sample sizes. Eight studies compared the aORs of
mortality in daptomycin- and linezolid-treated patients. Four studies were published as conference papers and there
was significant heterogeneity among these studies (I2 = 63%, p = 0.04). Daptomycin use was not associated with better
microbiological cure (daptomycin vs. linezolid, OR: 0.67, 95% CI: 0.42–1.06, p = 0.09). However, mortality was higher in
patients receiving daptomycin (OR: 1.43, 95% CI: 1.09–1.86, p = 0.009). Subgroup analysis of studies that reported aORs
indicated that daptomycin was associated with higher mortality (OR: 1.59, 95% CI: 1.02–2.50, p = 0.04). There was
no evidence of publication bias, but all enrolled studies were retrospective, had small sample sizes, and had substantial
limitations.
Conclusions: Although limited data is available, the current meta-analysis shows that linezolid treatment for VRE
bacteremia was associated with a lower mortality than daptomycin treatment. However, the results should be
interpreted cautiously because of limitations inherent to retrospective studies and the high heterogeneity
among studies. A large randomized trial is needed to confirm the present results.
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Background
Vancomycin-resistant enterococci (VRE) were first reported
in 1986 [1,2], and since then have become increasingly
responsible for hospital-acquired infections, especially
in intensive care units [3]. Currently, VRE bacteremia is a
significant independent predictor of mortality in patients
with enterococcal bloodstream infections (BSIs) [4].
Current treatment options are limited [5].
Linezolid, an oxazolidinone, is approved for treatment
of VRE infection but there are concerns about its use for
treatment of VRE bacteremia because it can suppress bone
marrow, it has bacteriostatic not bacteriocidal activity, and
resistant VRE strains have been reported [6,7]. Daptomycin,
a cyclic lipopeptide, exhibits rapid bactericidal activity
against VRE [8] and has been successfully used to treat
VRE bacteremia [9-11]. Daptomycin is not approved for
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the treatment of VRE bacteremia. Emerging studies
suggest daptomycin may have activity similar to that of
linezolid [12-19]. However, all of these studies had
small sample sizes and insufficient statistical power to
compare the efficacy of these drugs in treatment of
VRE bacteremia.
A large randomized controlled trial is the best method
to compare the efficacy of daptomycin and linezolid in
treatment of VRE bacteremia. However, such a trial was
halted prematurely because of logistic challenges [20]. A
search of the clinical trial registration database (www.
clinicaltrials.gov) indicated that there were no ongoing
trials comparing daptomycin and linezolid for the treat-
ment of VRE bacteremia. Recent systematic reviews and
meta-analyses showed that there was a tendency for
linezolid to provide better survival than daptomycin
[21,22]. However, possible confounders were not adjusted
for in the meta-analysis by Whang et al. [21]. In addition,
these meta-analyses included conference abstracts as well
as full papers [21,22]. Although inclusion of conference
papers might reduce publication bias, there may be differ-
ences in the results reported in conference abstracts and
subsequent publications [23]. In addition, several recent
studies [17,19,24] were not cited in these meta-analyses
[21,22].
The purpose of the present study was to determine
whether daptomycin is as effective as linezolid for treat-
ment of VRE bacteremia. We systematically reviewed the
literature on the effects of daptomycin and linezolid upon
the clinical outcomes of patients with VRE bacteremia and
synthesized all available data into a meta-analysis. In order
to control for possible confounders in each study, we ex-
tracted the adjusted effect estimates in analysis of mortal-
ity. We also examined the impact of statistical adjustment
of effect estimates, and whether the studies were full pa-
pers or conference papers.
Methods
We followed the recommendations of the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) [25]. No protocol of the present
review was previously published or registered.
Literature search
We searched PubMed, EMBASE, the Cochrane Library,
and ClinicalTrials.gov for relevant articles up to January 1,
2014. The following search terms were applied to articles
published since January 1950: Enterococcus AND (infec-
tion OR bacteremia) AND (linezolid OR daptomycin)
AND vancomycin resistant. The literature search was lim-
ited to English-language publications of human subjects.
We also reviewed the abstracts from the annual meetings
of the Infectious Disease Society of America and the
Interscience Conference on Antimicrobial Agents and
Chemotherapy. The references of 7 review articles on treat-
ments for VRE infections were examined to identify add-
itional studies not found in the computerized databases
[5,7,21,22,26-28].
Study selection
All included studies were clinical trials or observational
studies of the treatment of patients with VRE bacteremia
that reported daptomycin and linezolid treatment out-
comes simultaneously. Epidemiology studies that didn’t
report daptomycin and linezolid treatment outcomes were
excluded. Prophylaxis studies and studies lacking clinical
endpoint data were excluded. Study quality was assessed
using SIGN50, and studies with unacceptable quality were
excluded [29].
Data extraction, definitions, and outcomes
Two physician reviewers (Y.-C.C. and J.-T.W.) independ-
ently evaluated each study and abstracted the following:
study characteristics (design, country, time period), pa-
tient population (number of evaluated patients, disease
severity, underlying comorbidities, presence of infective
endocarditis), antibiotic usage (type, dosage), and adverse
events (anemia, leukopenia, thrombocytopenia, acute kid-
ney injury [AKI], elevated creatinine kinase [CK]).
The primary outcome was mortality. Clinical cure and
microbiological cure rate, as assessed by the investigators
of each study, were also recorded. Mortality was classified
as long-term (30 days, and overall in-hospital mortality)
or short-term (14 days, mortality at the end of therapy
[EOT], mortality within 7 days after EOT, and infection-
related mortality). For 8 studies, we also extracted and
compared the adjusted odds ratios (aORs) of mortality in
patients treated with daptomycin and linezolid. These
studies adjusted for possible confounders, such as under-
lying disease and disease severity.
Statistical analysis
Pooled odds ratios (ORs) and 95% confidence intervals
(CIs) of all outcomes were calculated using the DerSi-
monian–Laird random effects model. Heterogeneity was
estimated from the inverse-variance fixed-effect model.
Statistical heterogeneity among studies was assessed by
the χ2 test (p < 0.10 was defined as indicating signifi-
cant heterogeneity) and calculation of I2. Publication
bias was assessed by use of a funnel plot and the Egger
test. Univariate meta-regression analyses were per-
formed to examine the impacts of a reported aOR and
publication type on the results of the meta-analysis. All
statistical analyses were performed using STATA ver-
sion 12 (StataCorp, College Station, TX, USA) and Review
Manager 5.2. (The Nordic Cochrane Centre, Copenhagen,
Denmark).
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Results
Characteristics of included studies
A search of the 3 databases led to the initial identifica-
tion of 803 articles, 13 of which were ultimately included
in the analysis [12-19,24,30-33] (Figure 1). According to
the SIGN50 criteria, none of the 13 studies were classi-
fied as high quality. The study by Weinstock et al. [34]
(Figure 1) was classified as unacceptable quality and
excluded since that the study didn’t clearly define the
outcome and the exposure, which might result in detec-
tion bias. All enrolled studies were classified as acceptable
quality with some potential flaws in each study with an
associated risk of bias. The aORs of mortality for dapto-
mycin vs. linezolid treatment were extracted from our
previously published cohort study [24]. Raw data from
Chou et al. [17] were retrieved by email communication
for calculation of aORs.
Additional file 1: Table S1 and S2 describe the general
and detailed characteristics of the 13 eligible studies, all of
which were retrospective cohort studies with relatively
small sample sizes [12-19,24,30-33]. Two studies were
performed at multiple institutions [12,13] and 3 studies
focused on hematologic or neutropenic populations
[14,19,33]. Two studies were conducted in Taiwan
[17,24] and the others were conducted in the USA. Four
studies were published as conference papers [30-33]. All
studies reported mortality. Eight studies reported micro-
biological outcomes [12,15,16,18,30-33]. Eight studies re-
ported long-term mortality [12-14,16-19,33]; one study
reported 14-day mortality [24]; two studies reported mor-
tality at EOT [30,32]; one study reported mortality within
7 days after EOT [15]; and one study reported infection-
related mortality [31]. Eight studies compared the aORs of
mortality in daptomycin- and linezolid-treated patients
Potentially relevant studies
identified and screened for
retrieval (n =803)
Review articles (n = 323)
Studies retrieved for title and
abstract evaluation (n = 480)
Not original data reported (n = 111)
Not relevant (n = 74)
In vitro data (n = 85)
Epidemiology study (n = 110)
Studies retrieved for full-text
evaluation (n = 100)
Prophylaxis (n = 3)
Pediatric study (n = 15)
One arm in the same study (n = 68)
Unacceptable (n = 1)
Studies included in the
meta-analysis (n = 13)
Figure 1 Flow diagram of the systematic search and study selection process.
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[12,13,15-17,24,30,32]. These eight studies used multi-
variate analysis to adjust for factors such as age, sex,
Charlson comorbidity index, thrombocytopenia, timing of
antibiotics, intensive care unit stay, and disease severity
(e.g., APACHE II score, and shock) [12,13,15-17,24,30,32].




Overall, the 13 studies had data that compared the rela-
tive rates of raw mortality of 1188 patients who were
treated with daptomycin (n = 532) or linezolid (n = 656)
(Figure 2a). The results indicate that daptomycin was
associated with significantly higher mortality (OR: 1.43,
95% CI: 1.09–1.86, p = 0.009, I2 = 0%). However, there
were baseline differences of the 2 study groups, the
aORs for mortality in daptomycin- and linezolid-treated
patients were analyzed in further detail . We also per-
formed 3 subgroup analyses of these studies. In par-
ticular, we analyzed studies in which aORs were
reported or not (Figure 2b); studies in which long-term
and short-term mortality were reported (Figure 3a);
and studies that were published as full papers or con-
ference abstracts (Figure 3b).
Among studies that reported aORs, daptomycin was
associated with significantly higher mortality (Figure 2b,
747 patients, OR: 1.59, 95% CI: 1.02–2.50, p = 0.04,
I2 = 2%). However, among studies that did not report
aORs, daptomycin was not associated with signifi-
cantly higher mortality (Figure 2b, 441 patients, OR:
1.34, 95% CI: 0.85–2.11, p = 0.20, I2 = 0%). There was no
significant difference between two subgroups (p = 0.54).
Patients who received daptomycin had borderline
significantly higher long-term mortality (Figure 3a, 821
patients, OR: 1.44, 95% CI: 0.99–2.09, p = 0.06, I2 = 0%),
but not significantly short-term mortality (367 patients,
OR: 1.52, 95% CI: 0.67–3.46, p = 0.32, I2 = 46%).
Published full papers showed that patients who received
daptomycin had higher mortality (Figure 3b, 967 patients,
OR: 1.46, 95% CI: 1.02–2.09, p = 0.04, I2 = 0%). Conference
abstracts indicated no significant mortality differences,
and there was significant heterogeneity among these
studies (221 patients, OR: 1.41, 95% CI: 0.44–4.47,
p = 0.56, I2 = 63%).
Meta-regression analysis
Univariate meta-regression analyses indicated that the
results of the meta-analysis were not significantly af-
fected by reported OR (aOR vs. OR, p = 0.556), publica-
tion type (conference abstract vs. full paper, p = 0.948),
or outcome definition (long-term vs. short-term mortality,
p = 0.842).
Publication bias
A funnel plot of the 13 included studies indicates no
significant publication bias with respect to mortality
(Figure 4, slope coefficient = 0.574, p = 0.298). In addition,
the results of the test for small study effects indicated that
this was not significant (p = 0.710).
Clinical outcome, microbiological outcome, and relapse
Five studies (494 patients) reported clinical cure rates.
The results indicate no significant difference between li-
nezolid and daptomycin treatment (Figure 5a, daptomy-
cin vs. linezolid, OR: 0.85, 95% CI: 0.48–1.49, p = 0.57,
I2 = 38%). Eight studies (794 patients) reported micro-
biological cure rates. Linezolid treatment had a trend
for better microbiological cure (Figure 5b, daptomycin vs.
linezolid, OR: 0.67, 95% CI: 0.42–1.06, p = 0.09, I2 = 0%).
Five studies (452 patients) reported relapses of VRE
bacteremia. The results indicate that daptomycin use was
associated with significantly higher relapse rates (Figure 6,
daptomycin vs. linezolid, OR: 2.65, 95% CI: 1.03–6.78,
p = 0.04, I2 = 0%).
Adverse events
Five studies reported a priori-defined adverse events.
Hematologic adverse events could not be analyzed, be-
cause of differences in the reporting criteria. Although 3
studies reported that daptomycin was associated with
trends toward lower rates of thrombocytopenia (pooled
OR: 0.41, 95% CI: 0.14–1.18, p = 0.10, I2 = 0%) [12,15,31],
the other study reported that the linezolid group had a
shorter duration of thrombocytopenia (15.7 vs. 18.0 days)
[14]. Two studies (170 patients) provided data comparing
the relative rates of AKI due to daptomycin or linezolid
[12,14]. The results indicate that daptomycin was not as-
sociated with a significant risk of AKI (pooled OR: 1.59,
95% CI: 0.49–5.14, p = 0.44, I2 = 0%). Three studies (254
patients) had data comparing the relative rates of elevated
CK [12,14,15]. Again, daptomycin was not associated with
significant risk of elevated CK (pooled OR: 1.97, 95% CI:
0.37–10.46, p = 0.43, I2 = 0%) [15,24,30-32].
Discussion
Thirteen studies compared daptomycin and linezolid for
the treatment of VRE bacteremia, and these were all
relatively small retrospective cohort studies. Although
daptomycin has bactericidal activity against enterococci
[8], the present results surprisingly show daptomycin
was not associated with significantly better microbio-
logical cure rate than linezolid. In fact, consideration of
all 13 studies in the meta-analysis indicated that dapto-
mycin was associated with significantly higher mortality
than linezolid. In addition, subgroup analysis of studies
that reported aORs also showed linezolid treatment had
a more favorable outcome.
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Recent meta-analyses by Whang et al. [21] and Balli
et al. [22] indicated trends for increased survival with
linezolid compared to daptomycin in treatment of VRE
infections (OR: 1.3, p = 0.054 and OR: 1.41, p = 0.02, re-
spectively). There are some limitations of these meta-
analyses. Whang et al. [21] did not adjust for possible
confounders, so they may have used inaccurate ORs.
Balli et al. [22] reported that the daptomycin group had
higher mortality, and they confirmed this result when
aORs were pooled. It is noted that Furuya et al. [30] re-
ported the adjusted OR in their original paper. However,
Balli et al. [22] mis-classified Furuya et al. [30] into the
group of unadjusted OR. If this mis-classification is cor-
rected in the meta-analysis by Balli et al., [22] then
(b)
(a)
With adjusted odds ratio reported
No adjusted odds ratio reported
Figure 2 Forest plots of raw mortality and mortality in which aORs were and were not reported. (a) ORs of all 13 studies. (b) ORs of
studies that did (n = 8) and did not (n = 5) report aORs. Here and below, the vertical line indicates the “no difference” point of the 2 regimens
and the horizontal lines indicate 95% confidence intervals (CIs). ∎, odds ratio; ♦, pooled odds ratio for all studies.
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daptomycin group did not have higher mortality when
aORs were pooled in their paper.
Furthermore, these 2 previous meta-analyses included
conference abstracts as well as full papers. Although
inclusion of conference papers might result in less publi-
cation bias, there might be major differences in the results
and conclusions of conference abstracts and the subse-







Figure 3 Forest plots of long-term and short term mortality and of full papers and conference abstracts. (a) ORs of studies that reported
long-term (n = 8) and short-term (n = 5) mortality. (b) ORs of studies that were full papers (n = 9) and conference abstracts (n = 4).
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Figure 4 Funnel plot showing the absence of publication bias.
(a)
(b)
Figure 5 Forest plots of studies that reported clinical cure and microbiological cure. (a) ORs of studies that reported clinical cure (n = 5).
(b) ORs of studies that reported microbiological cure (n = 8).
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differences in the results of full papers and conference ab-
stracts, there was high heterogeneity among conference
abstracts (I2 = 62%). Furthermore, these conference ab-
stracts were missing important information, such as
outcome definitions and enrollment criteria. In general,
the information provided by conference papers is limited,
making it difficult to evaluate study quality [29].
Our results do not necessarily exclude the possibility
that bactericidal agents may be associated with better
outcomes [35]. In particular, various criteria are used to
define bactericidal effects in vitro, but such definitions
can be somewhat arbitrary in clinical settings [35]. Entero-
cocci are inherently less virulent organisms and generally
infect immunocompromised patients. In fact, most in-
fected patients have high Charlson comorbidity index
scores [12,15-17]. Under such clinical settings, it is even
more debatable whether bactericidal agents are better
than bacteriostatic agents.
All of the 13 studies in our meta-analysis were rela-
tively small retrospective cohort studies. Thus, there are
several important limitations.
First, daptomycin exhibits rapid concentration-dependent
bactericidal activity in vitro against Gram-positive organ-
isms, including enterococci [36]. Therefore, the daptomy-
cin dosage and minimum inhibitory concentration (MIC)
against specific VRE should be considered in outcome
analyses. A previous case series noted better outcomes
for patients given a daptomycin dosage of more than
6 mg/kg/day [11] and four studies of daptomycin dos-
age reported a mean or median dosage of 6 mg/kg/day
[12,13,15,18]. However, different daptomycin dosages
were used in four studies included in the present meta-
analysis (4.5–6 mg/kg/day [14], 3.7–8.8 mg/kg/day
[15], 3.4–10.4 mg/kg/day [18], and 4–9 mg/kg/day
[32]) and another four studies did not mention dapto-
mycin dosage [16,17,24,31]. Therefore, there may have
been under-dosing of daptomycin in some patients. In
contrast, linezolid was administered consistently at 600 mg
q12h [12-15,18,19,33]. In addition, only 6 studies reported
MICs [12,14,15,18,19,24], so the susceptibilities of the VRE
isolates to daptomycin and linezolid were not investigated
thoroughly.
Second, the time from bacteremia onset to initiation
of daptomycin or linezolid treatment was about 2 to
3 days [14-19]. However, in cases of septic shock, a delay
in administration of an effective antimicrobial agent by
only a few hours can decrease survival [37]. Thus, there
could have been an underestimate of the effectiveness of
daptomycin or linezolid treatment. It is also possible that
patients who survived for 2 to 3 days after bacteremia
onset until drug administration might have been healthier
to begin with. Thus the true effectiveness of daptomycin
or linezolid treatment might be over-estimated.
Third, we used the hard endpoint of “mortality” to
reduce the likelihood of misclassification bias, but the
different studies used different definitions of mortality.
Most of the enrolled studies reported long-term mortality
[12-14,16-18,33], but five studies reported short-term
mortality [15,24,30-32]. Fourteen-day mortality is suggested
for evaluating treatment outcome because this endpoint
can reduce potential bias due to the assignment of cause of
death, which can be problematic [38]. One of the included
studies reported that treatment and microbiological factors
affected 14-day morality but not 28-day mortality [24]. This
might be because enterococci generally infect compromised
hosts with multiple comorbidities, and that these comor-
bidities may be more significant causes of death. Some of
the included studies reported outcomes such as clinical or
microbiological cure. However, since all the studies were
retrospective, studies that report clinical cure might suffer
from recall bias or misclassification bias. There were no
pre-defined schedules for following blood cultures, so re-
sults regarding microbiologic cure are hard to interpret.
Fourth, there were various confounders among the in-
cluded studies. For example, patients in the daptomycin
groups had significantly higher rates of neutropenia [16]
and thrombocytopenia [15,17], whereas patients in the
linezolid groups were significantly older [12,18]. Meta-
analysis of the aORs of these 8 studies continued to
favor linezolid. Though these studies tried to adjust the
Figure 6 Forest plots of studies that reported relapse. ORs of studies that reported relapse (n = 5).
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confounders by using multivariate logistic regressions,
there are still residual confounding factors [39]. The
confounding by indications might result in difficulties in
comparing the treatment efficacies in such critical pa-
tients in nonrandomized studies. In addition, though all
studies reported that there are at least one set of blood
culture yielded VRE, however, important information
such as the foci of the bacteremic infection and the asso-
ciated therapy, such as catheter removal or not were not
clearly stated. Disease severity is an important factor
when evaluating treatment response. However, different
studies used different disease severity scores. Although
this can be adjusted for in individual studies, it is difficult
to analyze the impact of disease severity when combining
studies.
Adverse events, especially bone marrow suppression,
are another concern regarding the use of linezolid to
treat VRE bacteremia. The use of different definitions of
hematologic adverse events prevented us from pooling
and analyzing this data. However, the linezolid groups
apparently did not have a higher rate of adverse
hematologic events such as anemia, leukopenia, and
thrombocytopenia. In fact, an analysis of phase III trials
showed that linezolid was no more likely to cause adverse
effects than the drugs to which it was compared [40].
Other research indicated that thrombocytopenia and a
slightly increased risk of anemia occurred after 2 or more
weeks of linezolid treatment [41]. However, most of the
studies examined in the present meta-analysis adminis-
tered linezolid for only 10–14 days [14,15,18]. We also
found no significant evidence that daptomycin results in a
higher incidence of CK elevation than linezolid (pooled
OR: 1.97, p = 0.43).
Conclusions
Although limited data is available, the current meta-
analysis shows that linezolid treatment for VRE bacteremia
results in lower mortality than daptomycin treatment.
However, this should be interpreted cautiously because of
the limitations inherent to the retrospective studies in this
meta-analysis. Rather than concluding linezolid is superior
to daptomycin based on this meta-analysis, we strongly
recommend a large randomized trial with adequate dos-
ages to validate this result.
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